Skip to content
Search AI Powered

Latest Stories

Boots shifts focus on US market despite $3.1bn net loss

Walgreens Boots Alliance has announced the intention to reduce capital expenditures to ‘align’ cost structure with business performance

WBA, Boots' parent company, revealed the results for its fourth quarter of the financial year, showing three months to August 2023.


The reports published on 12 October show the loss of at least $1bn following a net loss of $3.1bn on an annual basis. This marks a decrease compared to a profit of $4.3bn in the previous financial year.

The loss was attributed in part to a $5.5 billion after-tax charge related to opioid claims and litigation during the period, as well as the comparison against a $2.5 billion after-tax gain from the company's investments in Village MD and Shields Health Solutions in the same period last year.

Ginger Graham, WBA’s Interim Chief Executive spoke about the company’s performance and its dedication to their customers and patients.

“In just six weeks, we have taken a number of steps to align our cost structure with our business performance, including planned cost reductions of at least $1bn, and lowered capital expenditures by approximately $600m.

“We anticipate seeing the impact of these actions in fiscal 2024, beginning in the second quarter. We are also intently focused on accelerating our profitability in the US healthcare segment,” said Graham.

The UK’s health and beauty retailer has made a $1bn (£820m) cost cut despite a UK sales boost in the “strong” final quarter of the year.

Earlier this year, Boots announced the plans to close 300 stores in the UK by next June which are in “close proximity to each other”.

They intend to reduce the number of stores in the UK from 2,200 in June of this year to 1,900. It's understood that the forthcoming cost-cutting measures will primarily target their US operations.

The following plans for the cost cut come just weeks before the announcement of Walgreens’ new chief executive, Tim Wentworth taking over the company on 23 October.

However, the UK’s performance was “stronger” than elsewhere in the group. In the year-ago quarter, the company witnessed a substantial uptick in comparable pharmacy sales, surging by 9.9 per cent.

Similarly, comparable retail sales in Boots UK also showed impressive growth, marking an 11.7 per cent increase, with positive performance seen across all product categories and a notable four per cent boost in foot traffic.

Seb James, Boots UK and Ireland managing director said: “I am really encouraged to see continued strong performance as the work that we have done to expand our ranges, drive value and innovate in beauty seems to be resonating extremely well with customers.

“We have great plans for the year ahead including our new Beauty store in Battersea, a further extension of our beauty category, expansion of our online doctor service and much more.”

More For You

Cargo plane unloading pharmaceuticals at US airport amid tariff concerns and stockpiling

Imports jumped in particular from Ireland, the top drug exporter to the US

Pic credit: iStock

Pharma imports to US surged in March as drugmakers look to avoid tariffs

Pharmaceutical imports to the US surged in March as drugmakers stocked up ahead of potential US tariffs on their products, which have historically been exempt from such fees.

Total imports of pharmaceutical products exceeded $50 billion in the month - the equivalent of 20 per cent of all pharmaceutical imports in 2024, according to data from a U.S. Commerce Department report on Tuesday.

Keep ReadingShow less
Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less